ANDREW GARNER: Open Payments
NPI 1821398678 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,196 in 85 payments from 12 companies in 2025. Trend: 2023 $1,773 · 2024 $910 · 2025 $2,196
Food & beverage: $2,094Education: $102
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $764 |
| Madrigal Pharmaceuticals | 11 | $471 |
| Janssen Biotech, Inc. | 13 | $359 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $174 |
| Ipsen Biopharmaceuticals, Inc | 2 | $49 |
| Aimmune Therapeutics, Inc. | 3 | $46 |
| Lilly USA, LLC | 2 | $36 |
| Ardelyx, Inc. | 2 | $31 |
| GENZYME CORPORATION | 1 | $25 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, SKYRIZI, XIFAXAN, ENTYVIO, LINZESS, IQIRVO.
Industry payments across MO — which companies pay providers there.
